Elliot Favus's Insider Trades & SAST Disclosures
Elliot Favus's most recent trade in Anavex Life Sciences Corporation was a trade of 145,000 Common Stock done at an average price of $11.7 . Disclosure was reported to the exchange on May 21, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Elliot Favus.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Sale of securities on an exchange or to another person at price $ 11.70 per share. | 21 May 2021 | 145,000 | 0 (0%) | 0% | 11.7 | 1,696,283 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 21 May 2021 | 50,000 | 87,500 (0%) | 0% | 0.9 | 46,000 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.96 per share. | 21 May 2021 | 50,000 | 145,000 (0%) | 0% | 3.0 | 148,000 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 21 May 2021 | 37,500 | 37,500 (0%) | 0% | 1.2 | 45,000 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 37,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 1,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.64 per share. | 21 May 2021 | 1,500 | 89,000 (0%) | 0% | 5.6 | 8,460 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.57 per share. | 21 May 2021 | 1,500 | 90,500 (0%) | 0% | 5.6 | 8,355 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.90 per share. | 21 May 2021 | 1,500 | 92,000 (0%) | 0% | 4.9 | 7,350 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.66 per share. | 21 May 2021 | 1,500 | 93,500 (0%) | 0% | 5.7 | 8,490 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 21 May 2021 | 1,500 | 95,000 (0%) | 0% | 6.1 | 9,165 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 1,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 1,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 1,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 1,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Sale of securities on an exchange or to another person at price $ 12.66 per share. | 24 Feb 2021 | 145,500 | 0 (0%) | 0% | 12.7 | 1,841,855 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.28 per share. | 24 Feb 2021 | 100,000 | 145,000 (0%) | 0% | 3.3 | 328,000 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.58 per share. | 24 Feb 2021 | 45,500 | 45,000 (0%) | 0% | 2.6 | 117,390 | Common Stock |
| Anavex Life Sciences Corpo... | Elliot Favus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 45,500 | 0 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges